Disc Medicine SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 22, 2026, 5:11 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Results of operations and financial condition · Other events · Financial statements and exhibits
AI summary, unreviewedDisc Medicine Prices Upsized $450 Million Common Stock Offering at $75.00 per Share, Reports $682.8 Million Preliminary Cash at September 30, 2026
8-KOct. 19, 2026, 7:08 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedDisc Medicine Reports Positive Phase 3 APOLLO Topline Results for Bitopertin in EPP, Meeting All Primary and Secondary Endpoints
8-KSept. 10, 2026, 8:48 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
8-KJuly 30, 2026, 8:32 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits